Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 19, 2014

View Archived Issues

Selective blockade of PTH activity by stapled peptide ATSP-10814

Clinical data show improved therapeutic efficacy of an antiasthmic drug in patient subtypes

Eisai establishes new joint research agreements for malaria

MGAT2 inhibitors designed for effects on obesity and related disorders

Series B financing at Pulmologix to fund new asthma drug

Pluristem pursues development strategy in Japan

MedGenesis and Pfizer enter into agreement for potential treatments for PD

Merck Serono and Lupin form strategic partnership targeting emerging markets

Quest PharmaTech and AD Biotech end investment agreement

Genisphere raises funds to develop targeted drug delivery technology

Trellis Bioscience and ContraFect's universal influenza treatment receives NIAID grant

Autologous mesenchymal stem cell transplant evaluated in phase I multiple sclerosis trial

Phase Ib data of synthetic cis-retinoid therapy for patients with genetic retinal defects

Clinical and preclinical data presented for a novel antibacterial, AAI-101

Treprost injection solution launched in Japan

Phase Ib/II trial of PEGPH-20 in combination with modified FOLFIRINOX to resume

Boehringer Ingelheim and CureVac to develop therapeutic cancer vaccine CV9-202

Neuraltus Pharmaceuticals' reports phase II data for NP-001

Alnylam Pharmaceuticals presents new preclinical results on ALN-CC5

Auxilium and QLT respond to Endo's acquisition proposal

Domainex discloses IKK-epsilon/TBK1 inhibitors

DPP IV inhibitors revealed in Hitgen patent

Bayer scientists report development of AKR1C3 inhibitors

Selvita describes 5-HT6 receptor antagonists

Novartis describes PI3K inhibitors in recent patent

Bayer to spin out MaterialScience polymers business and focus on healthcare and agrochemicals

Japanese approval of Aricept for dementia with Lewy bodies

FDA approves Trulicity for type 2 diabetes

Lymphoseek awarded U.S. orphan drug designation for head and neck cancers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...